100% Quality Guarantee
PhD-Level Technical Support
Key Features

PE Anti-Human CD37 Antibody [IPO-24] (AGEL2832)

SKU AGEL2832
Product Type Antibody
Antibody Type Monoclonal Antibody
Applications FCM
Reactivity Human
Host Species Mouse
Isotype Mouse IgG2b, κ
Clone IPO-24
Conjugation PE
€94 - €357

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

PE Anti-Human CD37 Antibody [IPO-24]

The CD37 Monoclonal Antibody (IPO-24) offered by AssayGenie is specifically designed for research involving the CD37 cell surface molecule. CD37 is known for its role in cell signaling and is a target for therapeutic antibodies in cancer treatments. This mouse monoclonal antibody, IPO-24, is highly specific for human CD37 and is validated for various applications, including flow cytometry and immunohistochemistry.CD37 is a crucial membrane protein involved in lymphocyte activation and proliferation, making it a key player in immune responses and cell cycle regulation. Research shows its potential as a therapeutic target in B-cell malignancies such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

The use of IPO-24 antibody enables the detection and analysis of CD37 expression in different cell types, providing valuable insights for immunology and oncology studies.By understanding the function and expression of CD37, researchers can further explore its role in disease pathology and develop targeted therapies that leverage its unique properties. The IPO-24 monoclonal antibody from AssayGenie offers researchers a reliable tool for investigating CD37 biology and its implications in cancer immunotherapy and other therapeutic approaches.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose